136 related articles for article (PubMed ID: 30214555)
1. A
Ye M; He Z; Dai W; Li Z; Chen X; Liu J
Oncol Lett; 2018 Oct; 16(4):4169-4178. PubMed ID: 30214555
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
3. Identifying a Novel Biomarker
Xiong Y; Yuan L; Chen L; Zhu Y; Zhang S; Liu X; Xiao Y; Wang X
J Cancer; 2018; 9(21):3912-3922. PubMed ID: 30410595
[TBL] [Abstract][Full Text] [Related]
4. Co-expression network analysis identified six hub genes in association with progression and prognosis in human clear cell renal cell carcinoma (ccRCC).
Yuan L; Chen L; Qian K; Qian G; Wu CL; Wang X; Xiao Y
Genom Data; 2017 Dec; 14():132-140. PubMed ID: 29159069
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of differentially expressed profiles and reconstruction of a competing endogenous RNA network in papillary renal cell carcinoma.
Luo Q; Cui M; Deng Q; Liu J
Mol Med Rep; 2019 Jun; 19(6):4685-4696. PubMed ID: 30957192
[TBL] [Abstract][Full Text] [Related]
6. Identifying biomarkers of papillary renal cell carcinoma associated with pathological stage by weighted gene co-expression network analysis.
He Z; Sun M; Ke Y; Lin R; Xiao Y; Zhou S; Zhao H; Wang Y; Zhou F; Zhou Y
Oncotarget; 2017 Apr; 8(17):27904-27914. PubMed ID: 28427189
[TBL] [Abstract][Full Text] [Related]
7. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.
Wagener N; Edelmann D; Benner A; Zigeuner R; Borgmann H; Wolff I; Krabbe LM; Musquera M; Dell'Oglio P; Capitanio U; Klatte T; Cindolo L; May M; Brookman-May SD;
PLoS One; 2017; 12(9):e0184173. PubMed ID: 28934212
[TBL] [Abstract][Full Text] [Related]
8. Whole lesion quantitative CT evaluation of renal cell carcinoma: differentiation of clear cell from papillary renal cell carcinoma.
Chen F; Huhdanpaa H; Desai B; Hwang D; Cen S; Sherrod A; Bernhard JC; Desai M; Gill I; Duddalwar V
Springerplus; 2015; 4():66. PubMed ID: 25694862
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
10. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
11. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
Meng H; Chen R; Li W; Xu L; Xu L
Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.
Zhou Z; Liu S; Zhang M; Zhou R; Liu J; Chang Y; Zhao Q
Dig Dis Sci; 2017 Oct; 62(10):2790-2800. PubMed ID: 28815403
[TBL] [Abstract][Full Text] [Related]
13. TOP2A Promotes Tumorigenesis of High-grade Serous Ovarian Cancer by Regulating the TGF-β/Smad Pathway.
Gao Y; Zhao H; Ren M; Chen Q; Li J; Li Z; Yin C; Yue W
J Cancer; 2020; 11(14):4181-4192. PubMed ID: 32368301
[No Abstract] [Full Text] [Related]
14. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
[TBL] [Abstract][Full Text] [Related]
15. Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.
Liu K; Ren Y; Pang L; Qi Y; Jia W; Tao L; Hu Z; Zhao J; Zhang H; Li L; Yue H; Han J; Liang W; Hu J; Zou H; Yuan X; Li F
Int J Clin Exp Pathol; 2015; 8(7):8311-35. PubMed ID: 26339402
[TBL] [Abstract][Full Text] [Related]
16. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma.
Douglas ML; Richardson MM; Nicol DL
Cancer; 2004 May; 100(10):2118-24. PubMed ID: 15139053
[TBL] [Abstract][Full Text] [Related]
17. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
Zhao H; Leppert JT; Peehl DM
PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatic analysis identifies potentially key differentially expressed genes in oncogenesis and progression of clear cell renal cell carcinoma.
Zhang H; Zou J; Yin Y; Zhang B; Hu Y; Wang J; Mu H
PeerJ; 2019; 7():e8096. PubMed ID: 31788359
[TBL] [Abstract][Full Text] [Related]
19. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
